Yahoo Finance

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

ArriVent BioPharma Reports Promising 16-Month Median Progression-Free Survival for Firmonertinib in First-Line NSCLC Patients with EGFR PACC Mutations

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
ascopubs.org

ALPACCA: Phase 3 trial of firmonertinib vs investigator’s choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha ...

A randomized phase III trial of chemo-immunotherapy vs immunotherapy alone for the vulnerable older adult with advanced non–small cell lung cancer: The ACHIEVE study—ECOG-ACRIN EA5221. This is an ASCO ...
Nasdaq

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...
Donna Moderna

Come distinguere l’argento dall’alpacca

L’alpacca è un materiale molto simile all’argento. Esso, infatti, è conosciuto anche con il nome di “argentone” oppure “argento tedesco” ed è costituito da un composto di rame, zinco e nichel (sono ...